

Heartland NCORP Publications April 2019 – Dec 2025

The list includes publications by HCR investigators that are not NCORP trials

Updated 1.7.26 - CK

Cheng E, Shi Q, Shields AF, Xue X, Rohan TE, Kuang C, Shergill AP, Ma C, Couture F, Kuebler JP, **Kumar P**, Tan B, Krishnamurthi SS, Ng K, O'Reilly EM, Brown JC, Meyerhardt JA. Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 1;117(12):2643-2652. doi: 10.1093/jnci/djaf281. PMID: 40996326; PMCID: PMC12629277. **CALGB 80702**

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, **Kumar P**, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Dec 4:e255144. doi: 10.1001/jamaoncol.2025.5144. Epub ahead of print. PMID: 41343176; PMCID: PMC12679421. **CALGB 80702**

Cahill K, Godfrey J, Nabhan C, Kline J, Riedell PA, Cohen KS, Narula S, Karrison TG, Robertson J, Karmali R, Venugopal P, Kim SH, Rapoport AP, Lee ST, Law J, **Fishkin PAS**, Isufi I, Velasco M, Kaminer L, Smith SM. A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11;9(21):5665-5675. doi: 10.1182/bloodadvances.2025017092. PMID: 40720747.

Sun H, Gada U, Alieldin R, Zhao T, Teets H, Bearden JD, **Esparaz BT**, Misleh J, Loh KP, Magnuson A, Mohamed MR, Gilmore N, Winslow TB, Williams AM, Li CS, Janelins MC. Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy. JNCI Cancer Spectr. 2025 Oct 31:pkaf105. doi: 10.1093/jncics/pkaf105. Epub ahead of print. PMID: 41172265.

Yilmaz S, Gilbride E, Hryniv S, Consagra W, Mohile SG, Culakova E, Canin B, Malhotra A, Tylock R, Hopkins JO, Liu JJ, Khatri J, LoCastro M, Anand M, Magnuson A, Loh KP. Peaceful Acceptance of Illness Among Older Adults With Advanced Cancer: A Randomized Clinical Trial. J Pain Symptom Manage. 2026 Jan;71(1):200-209. doi: 10.1016/j.jpainsymman.2025.10.007. Epub 2025 Oct 23. PMID: 41139045. **URCC-13070**

Gondi V, Pugh SL, Mehta MP, Wefel JS, Tomé WA, Sun AY, Grecula J, Redmond KJ, Fogh S, Gaspar L, Konski A, Bovi J, Robinson CG, Corn B, Videtic GM, Lok BH, **Yoon HA**, Heinzerling JH, DeNittis AS, McGarry RC, Devisetty K, Kundapur V, Wu AJ, McCarron EC, Thibault I, Simon EL, Baschnagel AM, Narayan S, Pollock J, Paulus R, Kachnic LA; NRG Oncology. Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. J Clin Oncol. 2025 Nov

10;43(32):3516-3525. doi: 10.1200/JCO-25-00221. Epub 2025 Aug 11. PMID: 40789106; PMCID: PMC12342643.

Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, Parsons SK, Unger JM, Perry AM, Casulo C, Bartlett NL, Tuscano JM, Hess BT, Torka P, **Kumar P**, Jacobs R, Song JY, Castellino SM, Kahl B, Leonard JP, Smith SM, Friedberg JW, Evens AM. Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. *J Clin Oncol*. 2025 Sep 20;43(27):2968-2973. doi: 10.1200/JCO-25-00204. Epub 2025 Jun 16. PMID: 40523203; PMCID: PMC12353409.

Altman BJ, Lin PJ, Mattick LJ, Outland EH, Bautista J, Li CS, Gada U, Morris KM, Knudsen-Clark AM, Mwangi D, DeRollo RE, Kleckner AS, Kleckner IR, Gilmore NJ, **Esparaz BT**, Curtis A, Conlin A, Monaco G, Hughey JJ, Mustian KM. Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia. *BJC Rep*. 2025 Sep 3;3(1):60. doi: 10.1038/s44276-025-00176-9. PMID: 40903493; PMCID: PMC12408818. **URCC-14040**

Freeman TJ, George TJ, Jacobs SA, Yothers G, Kolevska T, Feng H, Lipchik C, Maley S, Song N, Srinivasan A, Finnigan M, **Wade JL 3rd**, Buchschacher GL Jr, Al Baghdadi T, Shipstone A, Lin D, Puhalla SL, Allegra CJ, Wolmark N, Pogue-Geile KL. NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated. *Cancer Chemother Pharmacol*. 2025 Aug 9;95(1):80. doi: 10.1007/s00280-025-04802-8. PMID: 40782152 – **NSABP FC-11**

Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH, McGarry RC, Kundapur V, Devisetty K, Wu A, McCarron EC, Pollock J, Kanner AA, Feldman DB, Pugh SL, Kachnic LA, Movsas B. "Hope" Drives Quality of Life in Patients with Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003. *Int J Radiat Oncol Biol Phys*. 2025 Jul 2:S0360-3016(25)04519-5. doi: 10.1016/j.ijrobp.2025.06.3884. Epub ahead of print. PMID: 40614783. **NRG -CC003**

Wolfson JA, Grimes AC, Nuño MM, Ramakrishnan S, Dickens DS, Roth ME, Woods W, Adams KS, Alabi T, Beauchemin M, Levine JM, Scialla M, Boayue KB, Kerber CL, Ponce O, Vargas S, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, **Liu JJ**, Freyer DR, Sung L, Parsons SK. Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. *JNCI Cancer Spectr*. 2025 Apr 30;9(3):pkaf033. doi: 10.1093/jncics/pkaf033. PMID: 40238217; PMCID: PMC12121638. **ACCL16N1CD**

Gaston F, Polite B, Ullenius S, Fitzgerald S, **Bajaj M**. Sporadic Mucinous Adenocarcinoma of the Colon in an Adolescent Male: A Case Report and Review of the Literature. *J Pediatr Hematol Oncol*. 2025 Jul 1;47(5):219-223. doi: 10.1097/MPH.0000000000003031. Epub 2025 Apr 9. PMID: 40231812. – Not NCORP

Derman B, Tan C, Steinfield I, Wilson FR, Lin D, Wu B, Fernandez M, Fowler J, Paner-Straseviciute A, Kim N, Doyle M, Marshall A, Cheadle J, Keeping S, **Liu JJ**. Real-World

Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review. *Cancers (Basel)*. 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. PMID: 40227780; PMCID: PMC11988155. Not NCORP?

Raghav KPS, Guthrie KA, Tan B Jr, Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS, **Esparaz BT**, Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean EG, Kopetz S, Hochster HS, Philip PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With *RAS/BRAF* Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. *J Clin Oncol*. 2025 Apr 10;43(11):1348-1357. doi: 10.1200/JCO-24-01710. Epub 2025 Jan 6. PMID: 39761503; PMCID: PMC11975499. **S1613**

Ledet CB, Sener U, Johnson DR, **Ku K**, Halfdanarson TR. Fruquintinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Multiply Metastatic Rectal Cancer. *Clin Colorectal Cancer*. 2025 Mar;24(1):98-100. doi: 10.1016/j.clcc.2024.08.006. Epub 2024 Sep 2. PMID: 39343651. **Not NCORP**

Hernandez R, Nisar H, Kesavadas TK, McGee MC, **Gerstner GJ**, Martinez A, Boyce C, Ashrafi SA, Addington EL, Matthews AK, Elkefi S, Moskowitz JT. Assessing safety and feasibility of virtual reality intervention in patients with lung cancer: a pilot study. *Support Care Cancer*. 2025 Mar 25;33(4):318. doi: 10.1007/s00520-025-09338-4. PMID: 40131484. Not NCORP

Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, **Faller BA**, Agamah ES, Kasbari SS, Maliseti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K.: "Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929." *J Thorac Oncol*. 2025 Mar: :383-394. doi: 10.1016/j.jtho.2024.10.021. Epub 2024 Nov 4. PMID: 39505259. **S1929**

Pyzer AR, Dillon LW, Sharon E, Karrison TG, Zha Y, Fulton N, Gui G, Andrew GM, Streicher H, Sweet KL, Yaghmour G, **Liu JJ**, Jonas BA, Schimmer AD, Grant S, Zeidan AM, Hildebrandt GC, Lowrey CH, Mattison RJ, Palmisiano N, Salhotra A, Tzachanis D, Baer MR, Lin TL, Patel PA, Chen H, Stadler W, Odenike O, Larson RA, Gajewski TF, Hourigan CS, Stock W, Liu H. *Blood Adv*. 2025 Feb 10;bloodadvances.2024015176. doi: 10.1182/bloodadvances.2024015176. Online ahead of print. PMID: 39928953 **Not NCORP**

Winslow N, Boyle J, Miller W, Wang Y, **Geoffroy F**, Tsung AJ.: "Development of brain metastases in non-small-cell lung cancer: high-risk features." *CNS Oncol*. 2024 Dec 31;13(1):2395804. doi: 10.1080/20450907.2024.2395804. Epub 2024 Sep 12. PMID: 39264427; PMCID: PMC11404603. **Not NCORP**

Brown JC, Ma C, Shi Q, Couture F, Kuebler P, **Kumar P**, Tan B, Krishnamurthi S, Chang V, Goldberg RM, O'Reilly EM, Shields AF, Meyerhardt JA. Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). *J Natl Cancer Inst*. 2024 Dec 1;116(12):2032-2039. doi: 10.1093/jnci/djae203. PMID: 39180477; PMCID: PMC11630502. **80702**

Flanagan KC, Earls J, Hiken J, Wellinghoff RL, Ponder MM, McLeod HL, Westra WH, Vavinskaya V, Sutton L, Deichaite I, Macdonald OK, Welaya K, **Wade J 3rd**, Azzi G, Pippas AW, Slim J, Bank B, Sui X, Kossman SE, Shenkenberg TD, Alexander WL, Price KA, Ley J, Messina DN, Glasscock JI, Colevas AD, Cohen EEW, Adkins D, Duncavage EJ.: "Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study." J Immunother Cancer. 2024 Nov 3;12(11):e009573. doi: 10.1136/jitc-2024-009573. PMID: 39489541; PMCID: PMC11535711. **Not NCORP?**

Lin C, Patel AA, Huo D, Karrison T, van Besien K, Godwin J, Sher D, Weiner H, Green M, **Wade JL 3rd**, Klisovic R, Baer MR, Larson RA, Stock W, Odenike O.: "A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis." Blood Adv. 2024 Nov 26;8(22):5735-5743. doi: 10.1182/bloodadvances.2024013215. PMID: 39250708. **Not NCORP**

Arana-Chicas E, Lin PJ, Gada U, Sun H, Chakrabarti A, Mattick LJ, Rieth K, Chay CH, Ruzich J, **Esparaz BT**, Cupertino AP, Altman BJ, Vertino PM, Mohile SG, Mustian KM.: "The effect of YOCAS® yoga on cancer-related fatigue and quality of life in older (60+) vs. younger (≤ 59) cancer survivors: Secondary analysis of a nationwide, multicenter, phase 3 randomized controlled trial." J Geriatr Oncol. 2024 Nov;15(8):102076. doi: 10.1016/j.jgo.2024.102076. Epub 2024 Oct 4. PMID: 39368335. **URCC YOCAS study**

Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, **MacVicar GR**, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I Jr, Agarwal N.: "Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer." JAMA Netw Open. 2024 Oct 1;7(10):e2437871. doi: 10.1001/jamanetworkopen.2024.37871. PMID: 39374015; PMCID: PMC11581504. **S1216**

Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabé Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, **Gerstner G**, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV.: "Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study." Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 Aug 10. PMID: 39306923. **Not NCORP**

Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lambie A, **Kumar P**, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constone LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888. PMID: 39413375; PMCID: PMC11488644. **S1826**

Michel AM, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S, Anderson G, Arnold K, Law C, Pruthi S, Sandoval-Leon A, Shirley R, Perdekamp MG, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino DA, Wisinski K, DeYoung CA, Ross M, **Floyd J**, Kaster A, VanderWalde L, Saphner TJ, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Crew KD, Kukafka R.: "Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)." BMC Med Inform Decis Mak. 2024 Sep 27;24(1):272. doi: 10.1186/s12911-024-02691-0. PMID: 39334347; PMCID: PMC11430334. **S1904**

Reinders AN, Gao J, **Smile TD**.: "Human Papillomavirus (HPV)-Related Multiphenotypic Sinonasal Carcinoma With Intracranial Extension and Rapid Recurrence: A Case Report." Cureus. 2024 Sep 6;16(9):e68824. doi: 10.7759/cureus.68824. PMID: 39371782; PMCID: PMC11456359. **Not NCORP**

Huynh AN, Williams AM, Belcher EK, Van Haute P, Lotta LT, Thompson B, Netherby-Winslow C, Curtis A, **Esparaz BT**, Jorgensen C, Alberti S, Bentley E, Sun H, Culakova E, Janelins MC.: "Changes in S100 calcium-binding protein β (S100 β) and cognitive function from pre- to post-chemotherapy among women with breast cancer." Brain Behav Immun Health. 2024 Sep 8;41:100860. doi: 10.1016/j.bbih.2024.100860. PMID: 39391795; PMCID: PMC11466556. **URCC 10055**

Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, **Faller BA**, Kortmansky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB.: "Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)." J Natl Cancer Inst. 2024 Sep 1;116(9):1487-1494. doi: 10.1093/jnci/djae114. PMID: 38775718; PMCID: PMC11378308. **E7208**

Sadigh G, Duan F, An N, Gareen ID, Sicks J, Suga JM, Kehn H, **Mehan PT**, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Taylor MA, Park E, Wagner LI, Kircher SM, Carlos RC. Financial Hardship Among Patients With Early-Stage Colorectal Cancer. JAMA Netw Open. 2024 Sep 3;7(9):e2431967. doi: 10.1001/jamanetworkopen.2024.31967. PMID: 39287948; PMCID: PMC11409151. **EAQ162CD**

Gilmore N, Li Y, Seplaki CL, Sohn M, Yang Y, Li CS, Loh KP, Lin PJ, Kleckner A, Mohamed M, Vertino P, Peppone L, Mustian K, Kadambi S, Corso SW, **Esparaz B**, Giguere JK, Mohile S, Janelins MC.: "Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings." Oncologist. 2024 Aug 23:oyae212. doi: 10.1093/oncolo/oyae212. Epub ahead of print. Erratum in: Oncologist. 2024 Nov 4;29(11):e1633. doi: 10.1093/oncolo/oyae278. PMID: 39177095. **URCC 10055**

Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, Knight J, Mane S, Shergill A, **Kumar P**, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O'Reilly EM, Shields AF, Ogino S, Fuchs CS, Meyerhardt JA. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in *PIK3CA*-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 Aug 20;42(24):2853-2859. doi: 10.1200/JCO.23.01680. Epub 2024 Jun 18. PMID: 38889377; PMCID: PMC11392453. **SWOG 80702**

DeZern AE, Goll JB, Jensen TL, Nonavinkere Srivatsan S, Gillis NK, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Komrokji RS, Gore SD, Saber W, Bejar R, Walter MJ, Lindsley RC, Sherman S, DiFronzo N, Sekeres MA. Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study. Blood Neoplasia. 2024 Jun 12;1(3):100026. doi: 10.1016/j.bneo.2024.100026. PMID: 40453059; PMCID: PMC12082164.

McGuinness JE, Anderson GL, Mutasa S, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, **Kairouz SS**, Kuwajerwala N, Bevers TB, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser ML, Goodman GE, Brown PH, Ha R, Crew KD. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectr. 2024 Jul 1;8(4):pkae042. doi: 10.1093/jncics/pkae042. PMID: 38814817; PMCID: PMC11216724. **S0812**

Rapp SR, Dressler EV, Brown WM, **Wade JL 3rd**, **Le-Lindqwister N**, King D, Rowland KM, Weaver KE, Klepin HD, Shaw EG, Lesser GJ. "Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)". J Clin Oncol. 2024 Jul 20;42(21):2546-2557. doi: 10.1200/JCO.23.01100. Epub 2024 May 6. PMID: 38709986. **WF-97116**

Stearns V, Jegede OA, Chang VT, Skaar TC, Berenberg JL, Nand R, **Shafqat A**, Jacobs NL, Luginbuhl W, Gilman P, Benson AB 3rd, Goodman JR, Buchschacher GL Jr, Henry NL, Loprinzi CL, Flynn PJ, Mitchell EP, Fisch MJ, Sparano JA, Wagner LI. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Clin Cancer Res. 2024 Jul 1;30(13):2709-2718. doi: 10.1158/1078-0432.CCR-23-2137. PMID: 38640040; PMCID: PMC11287923. **E1Z11**

Crew KD, Anderson GL, Arnold KB, Stieb AP, Amenta JN, Collins N, Law CW, Pruthi S, Sandoval-Leon A, Bertoni D, Grosse Perdekamp MT, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino D, Wisinski KB, DeYoung CA, Ross M, **Floyd J**, Kaster A, Vander Walde L, Saphner T, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Kukafka R. Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a

cluster randomized controlled trial. Contemp Clin Trials. 2024 Jul;142:107564. doi: 10.1016/j.cct.2024.107564. Epub 2024 May 3. PMID: 38704119; PMCID: PMC11180561. **S1904**

Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, **Duncan CE**, Rodgers JP, Feng F, Sandler HM. Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 May 1;10(5):584-591. doi: 10.1001/jamaoncol.2023.7291. Erratum in: JAMA Oncol. 2024 Jun 1;10(6):833. doi: 10.1001/jamaoncol.2024.1062. PMID: 38483412; PMCID: PMC10941019. **GU003**

Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, **Jujjavarapu S**, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X." Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer." J Clin Oncol. 2024 May 1;42(13):1520-1530. doi: 10.1200/JCO.23.01080. Epub 2024 Feb 5. PMID: 38315963. **NSABP C-07 and C-08**

APR 2023 – MAR 2024

Sohal DPS, Boutin RD, Lenchik L, Kim J, Beg MS, Wang-Gillam A, **Wade JL 3rd**, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Chang VT. "Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505." J Gastrointest Surg. 2024 Mar;28(3):232-235. doi: 0.1016/j.gassur.2023.12.022. Epub 2024 Jan 19. PMID: 38445914. **SWOG S1505**

McBane RD 2nd, Loprinzi CL, Zemla T, Tafur A, Sanfilippo K, **Liu JJ**, Garcia DA, Heun J, Gundabolu K, Onitilo AA, Perepu U, Drescher MR, Henkin S, Houghton D, Ashrani A, Billett H, McCue SA, Lee MK, Le-Rademacher JG, Wysokinski WE; EVE trial investigators. Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial. J Thromb Haemost. 2024 Mar 25:S1538-7836(24)00169-7. doi: 0.1016/j.jtha.2024.03.011. Epub ahead of print. PMID: 38537780. – **NOT NCORP**

Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, **Jujjavarapu S**, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X." Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer." J Clin Oncol. 2024 Feb 5;JCO2301080. doi: 10.1200/JCO.23.01080. Epub ahead of print. PMID: 38315963. **NSABP C-07 and C-08**

Sun V, Guthrie KA, Crane TE, Arnold KB, Colby S, Freylersthe SG, Braun-Inglis C, Topacio R, Messick CA, Carmichael JC, Muskovitz AA, Nashawaty M, Bajaj M, Cohen SA, Flaherty DC, O'Rourke MA, Jones L, Krouse RS, Thomson CA. SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer. Cancer. 2024 Jul 1;130(13):2384-2394. doi: 10.1002/cncr.35264. Epub 2024 Feb 22. PMID: 38386696; PMCID: PMC11162313. **SWOG S1820**

Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, **Lyss AP**, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. "Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])." J Clin Oncol. 2024 Feb 9;JCO2301428. doi: 10.1200/JCO.23.01428. Epub ahead of print. PMID: 38335467. **NSABP B-46 and NSABP B-49**

Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Lee J, Affolter K, Mulvihill SJ, Beg MS, Wang-Gillam A, **Wade JL 3rd**, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty GL. "Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology." 2024 Jan 18:S0016-5085(24)00049-0. doi: 10.1053/j.gastro.2024.01.013. Epub ahead of print. PMID: 38244727. **NOT NCORP**

Wolfson JA, Grimes AC, Nuno M, Kerber CL, Ramakrishnan S, Beauchemin M, Dickens D, Levine JM, Roth ME, Scialla M, Woods W, Vargas S, Boayue KB, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, **Liu JJ**, Freyer DR, Sung L, Parsons SK. "Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL". JCO Oncol Pract. 2024 Jan 22:OP2300328. doi: 10.1200/OP.23.00328. Epub ahead of print. PMID: 38252911. **(COG through Alliance) ACCL16N1CD**

Kircher S, Duan F, An N, Gareen IF, Sicks JD, Sadigh G, Suga JM, Kehn H, **Mehan PT**, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Park ER, Wagner LI, Carlos RC.: "Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer." JAMA Netw Open. 2024 Jan 2;7(1):e2350844. doi: 10.1001/jamanetworkopen.2023.50844. PMID: 38194233; PMCID: PMC10777253. **ECOG-ACRIN EAQ162CD**

Kahl BS, Jegede OA, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, Weiss M, **Fishkin PA**, Fenske TS, Williams ME. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. J Clin Oncol. 2024 Jan 9;JCO2301912. doi: 10.1200/JCO.23.01912. Epub ahead of print. PMID: 38194625. **ECOG-ACRIN E4402**

Del Cid Fratti J, Paleru V, **Bajaj M**, Bhardwaj C. Correction: The toxic tango: TKI and ICI cardiotoxicities. Cardiooncology. 2024 Jan 18;10(1):4. doi: 10.1186/s40959-024-00200-w. Erratum for: Cardiooncology. 2023 Dec 6;9(1):44. PMID: 38238816; PMCID: PMC10795334. **NOT NCORP**

Jensen-Battaglia M, Mohammed M, Loh KP, Wells M, Tylock R, Ramsdale E, Canin B, Geer J, O'Rourke MA, **Liu JJ**, Seplaki CL, Mohile SG, Wildes TM. "Modifiable fall risk factors among older adults with advanced cancer: Secondary analysis of a cluster-randomized clinical trial." J Geriatr Oncol. 2023 Nov;14(8):101650. doi: 10.1016/j.jgo.2023.101650. Epub 2023 Oct 26. PMID: 37897888; PMCID: PMC10872468. **URCC 13070 (COACH)**

Flanagan KC, Earls J, Schillebeeckx I, Hiken J, Wellinghoff RL, LaFranzo NA, Bradley ZS, Babbitt J, Westra WH, Hsu R, Nadauld L, Mcleod H, Firth SD, Sharp B, Fuller J, Vavinskaya V,

Sutton L, Deichaite I, Bailey SD, Sandulache VC, Rendo MJ, Macdonald OK, Welaya K, **Wade JL 3rd**, Pippas AW, Slim J, Bank B, Saccaro SJ, Sui X, Akhtar A, Balaraman S, Kossman SE, Sonnier SA, Shenkenberg TD, Alexander WL, Price KA, Bane CL, Ley J, Messina DN, Glasscock JI, Cohen EEW, Adkins DR, Duncavage EJ. "Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma." *J Cancer Res Clin Oncol*. 2023 Nov;149(15):14125-14136. doi: 10.1007/s00432-023-05205-z. Epub 2023 Aug 8. PMID: 37552307; PMCID: PMC10590294. **NOT NCORP**

Mamounas EP, Bandos H, Rastogi P, Lembersky BC, Jeong JH, Geyer CE Jr, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, **Wade JL 3rd**, McCarron EC, Swain SM, Wolmark N. "Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer." *J Natl Cancer Inst*. 2023 Nov 8;115(11):1302-1309. doi: 10.1093/jnci/djad078. Erratum in: *J Natl Cancer Inst*. 2023 Sep 27;: PMID: 37184928; PMCID: PMC10637036. **NSABP B-42**

Gorak EJ, Otterstatter M, Al Baghdadi T, Gillis N, Foran JM, **Liu JJ**, Bejar R, Gore SD, Kroft SH, Harrington A, Saber W, Starczynowski D, Rollison DE, Zhang L, Moscinski L, Wilson S, Thompson J, Borchert C, Sherman S, Hebert D, Walker ME, Padron E, DeZern AE, Sekeres MA: "Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies." *Blood Adv*. 2023 Oct 24;7(20):6120-6129. doi: 10.1182/bloodadvances.2023010061. PMID: 37552083; PMCID: PMC10582385. **NHLBI-MDS**

Carthon BC, Kim SE, McDermott DF, Dutcher JP, Puligandla M, Manola J, Pins M, Carducci MA, Plimack ER, Appleman LJ, **MacVicar GR**, Kohli M, Kuzel TM, DiPaola RS, Haas NB.: "Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808" *Clin Genitourin Cancer*. 2023 Oct;21(5):546-554. doi: 10.1016/j.clgc.2023.06.012. Epub 2023 Jul 3. PMID: 37455214 **ECOG-ACRIN EA1808**

Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, dePrisco G, Yothers G, Dorth JA, Rahma OE, Russell MM, Gross HM, Jacobs SA, **Faller BA**, George S, Al Baghdadi T, Haddock MG, Valicenti R, Hong TS, George TJ.: "Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma" *J Clin Oncol*. 2023 Oct 10;41(29):4643-4651. doi: 10.1200/JCO.22.02525. Epub 2023 Jul 21. PMID: 37478389 **NRG-GI002**

Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, **MacVicar GR**, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr, Lerner SP."Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)" *Eur Urol*. 2023 Sep;84(3):341-347. doi: 10.1016/j.eururo.2023.06.014. Epub 2023 Jul 4. PMID: 37414705 **SWOG S1314**

Gadgeel SM, Miao J, Riess JW, Moon J, Mack PC, **Gerstner GJ**, Burns TF, Taj A, Akerley WL, Dragnev KH, Laudi N, Redman MW, Gray JE, Gandara DR, Kelly K: "Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)." Clin Cancer Res. 2023 Sep 15;29(18):3641-3649. doi: 10.1158/1078-0432.CCR-22-3947. PMID: 37233987; PMCID: PMC10526968 **SWOG S1507**

Navari RM, Le-Rademacher J, Smieliauskas F, Ruddy KJ, James Saphner T, Liu H, Harlos E, Onitilo AA, Giridhar K, **Singh PP**, Reddy PS, Chow S, Kruter F, Raptis G, Loprinzi CL.: "Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)." Oncologist. 2023 Aug 3;28(8):722-729. doi: 10.1093/oncolo/oyad140. PMID: 37284847; PMCID: PMC10400142. **Alliance 221602**

Abel GA, Hebert D, Lee C, Rollison D, Gillis N, Komrokji R, Foran JM, **Liu JJ**, Al Baghdadi T, Deeg J, Gore S, Saber W, Wilson S, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA.: "Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study." Blood Adv. 2023 Jul 25;7(14):3506-3515. doi: 10.1182/bloodadvances.2022009000. PMID: 37146263 **NHLBI-MDS**

Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, **Mehan PT**, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ.: "Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)" J Clin Oncol. 2023 Jun 20;41(18):3352-3362. doi: 10.1200/JCO.22.02394. Epub 2023 Mar 30. PMID: 36996380 **Alliance A031201**

Mohamed MR, Loh KP, Mohile SG, Sohn M, Webb T, Wells M, Yilmaz S, Tylock R, Culakova E, Magnuson A, Sun CL, Bearden J, Hopkins JO, **Faller BA**, Klepin HD.: "External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy" J Natl Compr Canc Netw. 2023 Mar;21(3):273-280.e3. doi: 10.6004/jnccn.2022.7094. PMID: 36898361 **URCC 13059 (GAP)**

Choueiri TK, Labaki C, Bakouny Z, Hsu CY, Schmidt AL, de Lima Lopes G Jr, Hwang C, Singh SRK, Jani C, Weissmann LB, Griffiths EA, Halabi S, Wu U, Berg S, O'Connor TE, Wise-Draper TM, Panagiotou OA, Klein EJ, Joshi M, Yared F, Dutra MS, Gatson NTN, Blau S, Singh H, Nanchal R, McKay RR, Nonato TK, Quinn R, Rubinstein SM, Puc M, Mavromatis BH, Vikas P, **Faller B**, Zaren HA, Del Prete S, Russell K, Reuben DY, Accordino MK, Singh H, Friese CR, Mishra S, Rivera DR, Shyr Y, Farmakiotis D, Warner JL.: "Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium" Lancet Reg Health Am. 2023 Mar;19:100445. doi: 10.1016/j.lana.2023.100445. Epub 2023 Feb 13. PMID: 36818595 **The COVID-19 and Cancer Consortium (CCC19) Registry**

----- MISSING 2023 MTG Publications

PUBS FOR APRIL 2022 MTG (Apr 2021-Apr 2022)

Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, **Faller BA**, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. "A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)" *Cancer*. 2022 Apr 1;128(7):1381-1391. doi: 10.1002/cncr.34063. Epub 2021 Dec 10. PMID: 34890045

Serritella AV, Shevrin D, Heath EI, **Wade JL**, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. "Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer" *Clin Cancer Res*. 2022 Apr 14;28(8):1549-1559. doi: 10.1158/1078-0432.CCR-21-4049. PMID: 35110415

Loh KP, Seplaki CL, Sanapala C, Yousefi-Nooraie R, Lund JL, Epstein RM, Duberstein PR, Flannery M, Culakova E, Xu H, McHugh C, Klepin HD, Lin PJ, Watson E, Grossman VA, **Liu JJ**, Geer J, O'Rourke MA, Mustian K, Mohile SG. "Association of Prognostic Understanding With Health Care Use Among Older Adults With Advanced Cancer: A Secondary Analysis of a Cluster Randomized Clinical Trial" *J Pain Symptom Manage*. 2022 Feb;63(2):301-310. doi: 10.1016/j.jpainsymman.2021.07.032. Epub 2021 Aug 8. PMID: 34371137

Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, Kuhn P, Hicks JB, Welter L, **Dy PA**, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy D, Puzstai L, Hortobagyi GN. "A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222" *Clin Cancer Res*. 2022 Feb 15;28(4):611-617. doi: 10.1158/1078-0432.CCR-21-3131. PMID: 34844978

Shankaran V, Unger JM, Darke AK, Suga JM, **Wade JL**, Kourlas PJ, Chandana SR, O'Rourke MA, Satti S, Liggett D, Hershman DL, Ramsey SD. "S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients" *J Natl Cancer Inst*. 2022 Mar 8;114(3):372-380. doi: 10.1093/jnci/djab210. PMID: 34981117

Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, **Faller B**, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S, McKay RR. "Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19" *JAMA Netw Open*. 2021 Nov 1;4(11):e2134330. doi: 10.1001/jamanetworkopen.2021.34330. PMID: 34767021

Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, **Anderson SA**, Zimmerman CT, O'Dea AP, Mirshahidi HR, Rodon

Ahnert J, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R: "A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)" Clin Cancer Res. 2021 Oct 29;clincanres.2182.2021. doi: 10.1158/1078-0432.CCR-21-2182. Online ahead of print. PMID: 3471619

Connolly RM, Zhao F, Miller KD, Lee MJ, Piekarczyk RL, Smith KL, Brown-Glaberman UA, Winn JS, **Faller BA**, Onitilo AA, Burkard ME, Budd GT, Levine EG, Royce ME, Kaufman PA, Thomas A, Trepel JB, Wolff AC, Sparano JA: "E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group" J Clin Oncol. 2021 Oct 1;39(28):3171-3181. doi: 10.1200/JCO.21.00944. Epub 2021 Aug 6. PMID: 34357781

Skinner H, Hu C, Tsakiridis T, Santana-Davila R, Lu B, Erasmus JJ, Doerner AJ, Videtic GMM, Coster J, Yang AX, Lee RY, Werner-Wasik M, Schaner PE, McCormack SE, **Esparaz BT**, McGarry RC, Bazan J, Struve T, Paulus R, Bradley JD.: "Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial" JAMA Oncol. 2021 Sep 1;7(9):1324-1332. doi: 10.1001/jamaoncol.2021.2318. PMID: 34323922

Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, **Wade JL**, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR: "Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)" J Immunother Cancer. 2021 Aug;9(8):e002973. doi: 10.1136/jitc-2021-002973. PMID: 34429332

Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, **Bajaj M**, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ.: "Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma." J Clin Oncol. 2021 Aug 20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. Epub 2021 May 4. PMID: 33945288 **Not NCTN**

Flannery MA, Mohile S, Culakova E, Norton S, Kamen C, Dionne-Odom JN, DiGiovanni G, Griggs L, Bradley T, Hopkins JO, **Liu JJ**, Loh KP.: "Completion of Patient-Reported Outcome Questionnaires Among Older Adults with Advanced Cancer" J Pain Symptom Manage. 2021 Aug 8:S0885-3924(21)00485-1. doi: 10.1016/j.jpainsymman.2021.07.032. Online ahead of print. PMID: 34371137

Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, **Faller BA**, Valicenti RK, Schefter TE, Moxley KM, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ: "Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial" JAMA Oncol. 2021 Aug 1;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683. PMID: 34196693

Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, **Faller BA**, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR: "A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)" Clin Lung Cancer. 2021 Jul;22(4):313-323.e1. doi: 10.1016/j.clcc.2021.02.009. Epub 2021 Feb 19. PMID: 33745865

Hensing TA, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, **Faller BA**, Dragnev KH, Kozono D, Vokes EE: "Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC" JTO Clin Res Rep. 2021 Jul 13;2(8):100208. doi: 10.1016/j.jtocrr.2021.100208. eCollection 2021 Aug. PMID: 34590049 **Not NCTN?**

Major A, Kline J, Karrison TG, **Fishkin PAS**, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM.: "Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas." Haematologica. 2021 Jul 29. doi: 10.3324/haematol.2021.278853. Online ahead of print. PMID: 34320785 **Not NCTN**

Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, **MacVicar GR**, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr: "A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)" Clin Cancer Res. 2021 May 1;27(9):2435-2441. doi: 10.1158/1078-0432.CCR-20-2409. Epub 2021 Feb 10. PMID: 33568346

Osarogiagbon RU, Vega DM, Fashoyin-Aje L, Wedam S, Ison G, Atienza S, De Porre P, Biswas T, Holloway JN, Hong DS, Wempe MM, Schilsky RL, Kim ES, **Wade JL 3rd**. "Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group". Clin Cancer Res. 2021 May 1;27(9):2408-2415. doi: 10.1158/1078-0432.CCR-20-3854. Epub 2021 Feb 9. PMID: 33563637

Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, **Yoon HA**, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J: Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Apr 22. doi: 10.1001/jamaoncol.2021.0687. Online ahead of print. PMID: 33885704.

Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC, **Liu JJ**, Schadt EE, Chen R, Li SD: "A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1

inhibitors in advanced non-small cell lung cancers” BMC Cancer. 2021 Apr 21;21(1):441. doi: 10.1186/s12885-021-08194-9. PMID: 33882890 **NOT NCTN**

Floyd Justin, Leja Monika: “Best Practices in Preventing Heartbreak: A look at a SWOG cancer control trial” The Cancer Letter V47, no 15, pages 35-37, April 16 2021

Ayers KL, Mullaney T, Zhou X, **Liu JJ**, Lee K, Ma M, Jones S, Li L, Redfern A, Jappe W, Liu Z, Goldsweig H, Yadav KK, Hahner N, Dietz M, Zimmerman M, Prentice T, Newman S, Veluswamy R, Wisnivesky J, Hirsch FR, Oh WK, Li SD, Schadt EE, Chen R.: “Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.” Oncologist. 2021 Apr 7. doi: 10.1002/onco.13780. Online ahead of print. PMID: 33829580 **NOT NCTN**

Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, **Kumar P**, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF.: “Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial” JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. PMID: 33821899.

JUNE 2020 – FEB 2021

Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerria M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, **Lyss A**, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M: “Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study”. Lancet Oncol. 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15. PMID: 33460574.

Osarogiagbon RU, Vega DM, Fashoyin-Aje L, Wedam S, Ison G, Atienza S, De Porre P, Biswas T, Holloway JN, Hong DS, Wempe MM, Schilsky RL, Kim ES, **Wade JL 3rd**. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res. 2021 Feb 9. doi: 10.1158/1078-0432.CCR-20-3854. Epub ahead of print. PMID: 33563637.

Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, Spira A, **Wade JL**, Stewart MD, Vega DM, Beaver JA, Denicoff AM, Ison G, Ivy SP, George S, Perez RP, Spears PA, Tap WD, Schilsky RL. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 Feb 9. doi: 10.1158/1078-0432.CCR-20-3852. Epub ahead of print. PMID: 33563632.

Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, **Wade JL**, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Kahl BS, Witzig TE. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. J Clin Oncol. 2021 Feb 8;JCO2001375. doi: 10.1200/JCO.20.01375. Epub ahead of print. [PMID: 33555941](#).

Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, **Wade JL 3rd**, Bennett CL, Scher HI, Nguyen PL, Gleave M, Morgan SC, Loblaw A, Sachdev S, Graham DL, Vapiwala N, Sion AM, Simons VH, Talcott J. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Jan 26;JCO2003256. doi: 10.1200/JCO.20.03256. Epub ahead of print. [PMID: 33497248](#).

Mohamed MR, Ramsdale E, Loh KP, Xu H, Patil A, Gilmore N, Obrecht S, Wells M, Nightingale G, Juba KM, **Faller B**, Onitilo A, Bradley T, Culakova E, Holmes H, Mohile SG. Association of Polypharmacy and Potentially Inappropriate Medications With Physical Functional Impairments in Older Adults With Cancer. J Natl Compr Canc Netw. 2021 Jan 22;1-8. doi: 10.6004/jnccn.2020.7628. Epub ahead of print. [PMID: 33482631](#).

Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, **Wade JL 3rd**, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Jan 21:e207328. doi: 10.1001/jamaoncol.2020.7328. Epub ahead of print. [PMID: 33475684](#).

Kurbegov D, Hurley P, Waterhouse DM, Robert NJ, Nowakowski GS, Thompson MA, Bruinooge SS, Schilsky RL, Byatt L, Dempsey K, Dawson C, Hofacker J, **Liu J**, MacDougall AK, Kim ES. Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncol Pract. 2021 Jan;17(1):41-51. doi: 10.1200/OP.20.00821. Epub 2021 Jan 6. [PMID: 33405975](#).

Kah Poh Loh ,Enrique Soto Pérez de Celis, Paul R. Duberstein, Eva Culakova, Ronald M. Epstein, Huiwen Xu MHA, Sindhuja Kadambi, Marie Flannery, Allison Magnuson, Colin McHugh, Kelly M. Trevino, Gina Tuch, Erika Ramsdale, Reza Yousefi-Nooraie, Margaret Sedenquist, **Jane Jijun Liu**, Nataliya Melnyk, Jodi Geer BA, Supriya G. Mohile: "Patient and caregiver agreement on prognosis estimates for older adults with advanced cancer" Cancer . 2020 Jan 1;127(1):149-159. doi: 10.1002/cncr.33259. Epub 2020 Oct 9. [PMID: 33036063](#)

Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, **Wade JL 3rd**, Fisch MJ, Henry NL, Hershman DL, Gralow J. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncol. 2020 Dec 17:e206353. doi: 10.1001/jamaoncol.2020.6353. Epub ahead of print. [PMID: 33331905](#)

Jacobs SA, Lee JJ, George TJ, **Wade JL 3rd**, Stella PJ, Wang D, Sama AR, Piette F, Pogue-Geile KL, Kim RS, Gavin PG, Lipchik C, Feng H, Wang Y, Finnigan M, Kiesel BF, Beumer JH, Wolmark N, Lucas PC, Allegra CJ, Srinivasan A. Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clin Cancer Res. 2020 Nov 17. doi: 10.1158/1078-0432.CCR-20-1831. Epub ahead of print. PMID: 33203645.

Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, **Faller BA**, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A: "Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial" Nat Med. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5. PMID: 33020646

Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, **Faller BA**, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5. PMID: 33020646.

Loh KP, Soto-Perez-de-Celis E, Duberstein PR, Culakova E, Epstein RM, Xu H, Kadambi S, Flannery M, Magnuson A, McHugh C, Trevino KM, Tuch G, Ramsdale E, Yousefi-Nooraie R, Sedenquist M, **Liu JJ**, Melnyk N, Geer J, Mohile SG: "Patient and caregiver agreement on prognosis estimates for older adults with advanced cancer" Cancer. 2020 Oct 9. doi: 10.1002/cncr.33259. Online ahead of print. PMID: 33036063

Steffen McLouth LE, Zhao F, Owonikoko TK, Feliciano JL, Mohindra NA, Dahlberg SE, **Wade JL 3rd**, Srkalovic G, Lash BW, Leach JW, Leal TA, Aggarwal C, Cella D, Ramalingam SS, Wagner LI: "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" Cancer Med. 2020 Oct;9(20):7511-7523. doi: 10.1002/cam4.3416. Epub 2020 Aug 28. PMID: 32860331

Peoples AR, Pigeon WR, Li D, Garland SN, Perlis ML, Inglis JE, Vinciguerra V, Anderson T, Evans LS, **Wade JL**, Ossip DJ, Morrow GR, Wolf JR: "Association between pre-treatment sleep disturbance and radiation therapy-induced pain in 573 women with breast cancer" J Pain Symptom Manage. 2020 Aug 5:S0885-3924(20)30651-5. doi: 10.1016/j.jpainsymman.2020.07.041. Online ahead of print. PMID: 32768555

Duvvuri PD, **Liu J**, Bhardwaj C: "A 59-Year-Old Woman With Shortness of Breath and Chest Pain" Chest. 2020 Aug;158(2):e65-e69. doi: 10.1016/j.chest.2020.02.059. PMID: 32768078

Wong SF, Unger JM, **Wade JL 3rd**, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR Jr, **Floyd JD**, **Esparaz BT**, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM: "A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor

inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013” J Patient Rep Outcomes. 2020 Jul 8;4(1):54. doi: 10.1186/s41687-020-00220-x. PMID: [32642992](#).

Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, **Wade JL 3rd**, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS: “Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma” Ann Surg. 2020 Jul 24. doi: 10.1097/SLA.0000000000004155. Online ahead of print. PMID: [32740235](#)

Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, **Liu JJ**, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH: “Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)” Clin Lung Cancer. 2020 Jun 12:S1525-7304(20)30189-3. doi: 10.1016/j.clcc.2020.06.007. Online ahead of print. PMID: [32807654](#)

Hershman DL, Unger JM, Hillyer GC, Moseley A, Arnold KB, Dakhil SR, **Esparaz BT**, Kuan MC, Graham ML 2nd, Lackowski DM, Edenfield WJ, Dayao ZR, Henry NL, Gralow JR, Ramsey SD, Neugut AI.: “Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105” J Clin Oncol. 2020 Jul 1;38(19):2122-2129. doi: 10.1200/JCO.19.02699. Epub 2020 May 5. PMID: [32369401](#)

Ryan Wolf J, Gewandter JS, Bautista J, Heckler CE, Strasser J, **Dyk P**, Anderson T, Gross H, Speer T, Dolohanty L, Bylund K, Pentland AP, Morrow GR: “Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial.” Support Care Cancer. 2020 Jul;28(7):3303-3311. doi: 10.1007/s00520-019-05166-5. Epub 2019 Nov 22. PMID: [31758326](#)

Wong SF, Unger JM, **Wade JL 3rd**, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, **Velasco MR Jr**, **Floyd JD**, **Esparaz BT**, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moynihan CM.: “A Prospective Study to Validate the Functional Assessment of Cancer Therapy (FACT) for Epidermal Growth Factor Receptor Inhibitor (EGFRI)-induced Dermatologic Toxicities FACT-EGFRI 18 Questionnaire: SWOG S1013” J Patient Rep Outcomes. 2020 Jul 8;4(1):54. doi: 10.1186/s41687-020-00220-x. PMID: [32642992](#)

Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, **Wade JL**, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE.: “A Randomized Phase 2 Study of Temsirolimus and Cetuximab Versus Temsirolimus Alone in recurrent/metastatic, Cetuximab-Resistant Head and Neck Cancer: The MAESTRO Study” Cancer. 2020 Jul 15;126(14):3237-3243. doi: 10.1002/cncr.32929. Epub 2020 May 4. PMID: [32365226](#)

Levit LA, Byatt L, **Lyss AP**, Paskett ED, Levit K, Kirkwood K, Schenkel C, Schilsky RL.: "Closing the Rural Cancer Gap" JCO Oncol Pract. 2020 Jul;16(7):422-430. doi: 10.1200/OP.20.00174. Epub 2020 Jun 23. [PMID: 32574128](#)

MARCH 2019-JULY 2020

Hershman DL, Unger JM, Hillyer GC, Moseley A, Arnold KB, Dakhil SR, **Esparaz BT**, Kuan MC, Graham ML 2nd, Lackowski DM, Edenfield WJ, Dayao ZR, Henry NL, Gralow JR, Ramsey SD, Neugut AI.: "Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105" J Clin Oncol. 2020 Jul 1;38(19):2122-2129. doi: 10.1200/JCO.19.02699. Epub 2020 May 5. [PMID: 32369401](#)

Ryan Wolf J, Gewandter JS, Bautista J, Heckler CE, Strasser J, **Dyk P**, Anderson T, Gross H, Speer T, Dolohanty L, Bylund K, Pentland AP, Morrow GR: "Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial." Support Care Cancer. 2020 Jul;28(7):3303-3311. doi: 10.1007/s00520-019-05166-5. Epub 2019 Nov 22. [PMID: 31758326](#)

Wong SF, Unger JM, **Wade JL 3rd**, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, **Velasco MR Jr**, **Floyd JD**, **Esparaz BT**, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM.: "A Prospective Study to Validate the Functional Assessment of Cancer Therapy (FACT) for Epidermal Growth Factor Receptor Inhibitor (EGFRI)-induced Dermatologic Toxicities FACT-EGFRI 18 Questionnaire: SWOG S1013" J Patient Rep Outcomes. 2020 Jul 8;4(1):54. doi: 10.1186/s41687-020-00220-x. [PMID: 32642992](#)

Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, **Wade JL**, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE.: "A Randomized Phase 2 Study of Temsirolimus and Cetuximab Versus Temsirolimus Alone in recurrent/metastatic, Cetuximab-Resistant Head and Neck Cancer: The MAESTRO Study" Cancer. 2020 Jul 15;126(14):3237-3243. doi: 10.1002/cncr.32929. Epub 2020 May 4. [PMID: 32365226](#)

Levit LA, Byatt L, **Lyss AP**, Paskett ED, Levit K, Kirkwood K, Schenkel C, Schilsky RL.: "Closing the Rural Cancer Gap" JCO Oncol Pract. 2020 Jun 23:OP2000174. doi: 10.1200/OP.20.00174. Online ahead of print. [PMID: 32574128](#)

Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock: "A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors" Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. [PMID: 31969335](#)

Hertler A, Chau S, Khetarpal R, Bassin E, Dang J, Koppel D, Damarla V, **Wade J**.: "Utilization of Clinical Pathways Can Reduce Drug Spend Within the Oncology Care Model" JCO Oncol Pract. 2020 May;16(5):e456-e463. doi: 10.1200/JOP.19.00753. Epub 2020 Mar 20.

PMID: 32196401

Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, **Wade JL**, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE.: "A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study" *Cancer*. 2020 Jul 15;126(14):3237-3243. doi: 10.1002/cncr.32929. Epub 2020 May 4. PMID: 32365226

Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, **Lyss AP**, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV: "Personalized Management of Chemotherapy Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)" *J Clin Pharmacol*. 2020 Apr;60(4):444-452. doi: 10.1002/jcph.1559. Epub 2019 Dec 4. PMID: 31802506

Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA; for NRG Oncology: "Hippocampal Avoidance during Whole-Brain Radiotherapy plus Memantine for Patients with Brain Metastases: Phase III Trial NRG Oncology CC001" *J Clin Oncol*. 2020 Apr 1;38(10):1019-1029. doi: 10.1200/JCO.19.02767. Epub 2020 Feb 14. PMID: 32058845

Hwang ES, Hyslop T, Hendrix L, Duong, S, Bedrosian I, Price E, Caudle A, Hieke, T, Guenther J, Hudis C, Winer E, **Lyss AP**, Dickson-Witmer D, Hoefler R, Ollila DW, Hardman T, Marks J, Yi-Chen Y, Krings G, Esserman L, Hylton N: "Phase II Single Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: Alliance/CALGB 40903 (Alliance)" *J Clin Oncol*. 2020 Apr 20;38(12):1284-1292. doi: 10.1200/JCO.19.00510. Epub 2020 Mar 3. PMID: 32125937

Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtneess B, Nangia CS, Barzi A, Schneider CJ, **Liu JJ**, Dotan E, Guthrie KA, Hochster HS: "Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201" *J Clin Oncol*. 2020 Feb 10;38(5):472-479. doi: 10.1200/JCO.19.00925. Epub 2019 Dec 9. PMID: 31815582

Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, **Wade J**, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR: "Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing" *Clin Cancer Res*. 2020 Jan 1;26(1):18-24. doi: 10.1158/1078-0432.CCR-19-1483. Epub 2019 Sep 26. PMID: 31558477

Sonbol MB, Mountjoy LJ, **Firwana B**, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T: "The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical

Trials” JAMA Oncol. 2019 Dec 19:e194489. doi: 10.1001/jamaoncol.2019.4489. [Epub ahead of print] [PMID: 31855256](#)

Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, **Liu JJ**, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK: “The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes” Leuk Lymphoma. 2019 Dec;60(13):3161-3171. doi: 10.1080/10428194.2019.1616186. Epub 2019 May 21. [PMID: 31111762](#)

Mohile SG, Epstein RM, Hurria A, Heckler CE, Canin B, Culakova E, Duberstein P, Gilmore N, Xu H, Plumb S, Wells M, Lowenstein LM, Flannery MA, Janelins M, Magnuson A, Loh KP, Kleckner AS, Mustian KM, Hopkins JO, **Liu JJ**, Geer J, Gorawara-Bhat R, Morrow GR, Dale W: “Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program” JAMA Oncol. 2019 Nov 7:1-9. doi: 10.1001/jamaoncol.2019.4728. [Epub ahead of print] [PMID: 31697365](#)

Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, **Floyd JD**, Garber JE, Hofstadter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR: “Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update” J Clin Oncol. 2019 Sep 3;JCO1901472. doi: 10.1200/JCO.19.01472. [Epub ahead of print] [PMID: 31479306](#)

Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, **Lyss AP**, Horn L, Stinchcombe TE, Schiller JH: “Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508” J Clin Oncol. 2019 Sep 10;37(26):2360-2367. doi: 10.1200/JCO.19.01006. Epub 2019 Jul 30. [PMID: 31361535](#)

Lori M. Minasian, Eileen Dimond, Myrtle Davis, Bishow Adhikari, Richard Fagerstrom, Carol Fabian, **Justin Floyd**, Joseph M. Unger, Pamela S. Douglas, Karen M. Mustian, Eric J. Chow, Steven Lipshultz, W. Gregory Hundley, Saro H. Armenian, Bonnie Ky: “The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity” JACC CardioOncol. 2019 Sep;1(1):105-113. doi: 10.1016/j.jacc.2019.08.007. Epub 2019 Sep 24. [PMID: 32529192](#)

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, **Lyss AP**, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S: “Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study” Clin Breast Cancer. 2019 Aug;19(4):225-235.e2. doi: 10.1016/j.clbc.2019.02.010. Epub 2019 Mar 6. [PMID: 30928413](#)

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, **Lyss AP**, Osborne CK,

Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S: "Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study" Clin Breast Cancer. 2019 Aug;19(4):225-235.e2. doi: 10.1016/j.clbc.2019.02.010. Epub 2019 Mar 6. [PMID: 30928413](#)

Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, **Kairouz SS**, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouster M, Goodman GE, Brown PH: "Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812)." Cancer Prev Res (Phila). 2019 Jul;12(7):481-490. doi: 10.1158/1940-6207.CAPR-18-0444. Epub 2019 May 28. [PMID: 31138522](#)

Barger S, Sullivan SD, Bell-Brown A, Bott B, Ciccarella AM, Golenski J, Gorman M, Johnson J, Kreizenbeck K, Kurttila F, Mason G, Myers J, Seigel C, **Wade JL 3rd**, Walia G, Watabayashi K, Lyman GH, Ramsey S: "Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care" BMC Med Res Methodol. 2019 Jun 11;19(1):119. doi: 10.1186/s12874-019-0764-2. [PMID: 31185918](#)

Hong D, Rasco D, **Veeder M**, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.: "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients With Pretreated Solid Tumors" Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21. [PMID: 31230047](#)

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, **Wade JL 3rd**, Hershman DL: "Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202" Cancer. 2019 Jun 15;125(12):2123-2129. doi: 10.1002/cncr.32024. Epub 2019 Mar 12. [PMID: 30861098](#)

Langer CJ, Redman MW, **Wade JL 3rd**, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA: "Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)" J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414-9. doi: 10.1016/j.jtho.2019.05.029. [Epub ahead of print] [PMID: 31158500](#)

Magnuson A, Lei L, Gilmore N, Kleckner AS, Lin FV, Ferguson R, Hurria A, Wittink MN, **Esparaz BT**, Giguere JK, Misleh J, Bautista J, Mohile SG, Janelins MC: "Longitudinal Relationship Between Frailty and Cognition in Patients 50 Years and Older with Breast Cancer" J Am Geriatr Soc. 2019 May;67(5):928-936. doi: 10.1111/jgs.15934. [PMID: 31034595](#)

Loh KP, Kleckner IR, Lin PJ, Mohile SG, Canin BE, Flannery MA, Fung C, Dunne RF, Bautista J, Culakova E, Kleckner AS, Peppone LJ, Janelins M, McHugh C, Conlin A, Cho JK, Kasbari

S, **Esparaz BT**, Kuebler JP, Mustian KM: "Effects of a Home-based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy" J Am Geriatr Soc. 2019 May;67(5):1005-1011. doi: 10.1111/jgs.15951. PMID: 31034591

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, **Mehan PT**, Gaur R, Seery T, Guthrie KA, Hochster HS: "Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313" J Clin Oncol. 2019 May 1;37(13):1062-1069. doi: 10.1200/JCO.18.01295. Epub 2019 Feb 28. PMID: 30817250

Kehoe LA, Xu H, Duberstein P, Loh KP, Culakova E, Canin B, Hurria A, Dale W, Wells M, Gilmore N, Kleckner AS, Lund J, Kamen C, Flannery M, Hoerger M, Hopkins JO, **Liu JJ**, Geer J, Epstein R, Mohile SG: "Quality of Life of Caregivers of Older Patients with Advanced Cancer." J Am Geriatr Soc. 2019 May;67(5):969-977. doi: 10.1111/jgs.15862. Epub 2019 Mar 29 PMID: 30924548

Gilmore N, Kadambi S, Lei L, Loh KP, Mohamed M, Magnuson A, Cole S, **Esparaz BT**, Giguere JK, Mohile S, Janelins M: "Associations of inflammation with frailty in patients with breast cancer aged 50 and over receiving chemotherapy" J Geriatr Oncol. 2020 Apr;11(3):423-430. doi: 10.1016/j.jgo.2019.04.001. Epub 2019 Apr 13. PMID: 30992181